Literature DB >> 8150978

Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci.

B J Buschelman1, R N Jones, M J Bale.   

Abstract

This comparative study determined the effect of blood on the antienterococcal activities of the newer cephalosporins. Standardized disk diffusion susceptibility tests were performed with 57 strains of enterococci (30 Enterococcus faecalis strains) on Mueller-Hinton agar with and without 5% sheep blood supplementation. Twelve cephalosporins representing five different structural groups (based on the 7-alpha position substitution) were tested. The greatest frequency of activity enhancement by blood was observed with cefdaloxime and cefdinir (7-alpha hydroxyimino group) against E. faecalis. Cephalosporins with a 7-alpha methoxyimino group (cefpodoxime, cefepime, and cefpirome) had marked increases in zone diameters (3 to > 9 mm) when tested with the blood supplement. Cephems with 7-alpha amino or carboxy substitutions did not demonstrate any enhanced activity. Awareness of this phenomenon is important for the interpretation and accuracy of cephalosporin susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150978      PMCID: PMC263080          DOI: 10.1128/jcm.32.2.565-567.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.

Authors:  R N Jones; M E Erwin; B B Gooding
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis.

Authors:  D F Sahm; C N Baker; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

3.  Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.

Authors:  H C Neu; G Saha; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  Effect of blood product medium supplements on the activity of cefotaxime and other cephalosporins against Enterococcus faecalis.

Authors:  G M Eliopoulos; E Reiszner; S Willey; W J Novick; R C Moellering
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Mar-Apr       Impact factor: 2.803

5.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

6.  Activity of cefotaxime against enterococci.

Authors:  R C Moellering; G M Eliopoulos
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

7.  Cefotaxime and cephalosporins: adverse reactions in perspective.

Authors:  C R Smith
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins.

Authors:  D F Sahm; C N Baker; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

9.  BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1988-01       Impact factor: 2.803

10.  Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Authors:  R N Jones; C Thornsberry; A L Barry; L Ayers; S Brown; J Daniel; P C Fuchs; T L Gavan; E H Gerlach; J M Matsen
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

  10 in total
  3 in total

Review 1.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 2.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Effects of different test conditions on MICs of food animal growth-promoting antibacterial agents for enterococci.

Authors:  P Butaye; L A Devriese; F Haesebrouck
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.